The use of typhoid vaccines in Asia: The DOMI experience

被引:30
作者
Ochiai, R. Leon
Acosta, Camilo J.
Agtini, Magdarina
Bhattacharya, Sujit K.
Bhutta, Zulfiqar A.
Do, Canh Gia
Dong, Baiqing
Chen, Xinguang
Stanton, Bonita
Kaljee, Linda
Nyamete, Andrew
Galindo, Claudia M.
von Seidlein, Lorenz
DeRoeck, Denise
Jodar, Luis
Clemens, John D.
机构
[1] Int Vaccine Inst, Seoul 151818, South Korea
[2] Natl Inst Hlth Res & Dev, Jakarta, Indonesia
[3] Natl Inst Cholera & Enter Dis, Kolkata, W Bengal, India
[4] Aga Khan Univ, Dept Paediat, Karachi 74800, Pakistan
[5] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[6] Guangxi Ctr Dis Control & Prevent, Guangxi, Peoples R China
[7] Wayne State Univ, Sch Med, Childrens Hosp Michigan, Prevent Res Ctr,Carman & Ann Adams Dept Pediat, Detroit, MI 48202 USA
[8] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
关键词
D O I
10.1086/518144
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Two currently licensed typhoid vaccines have been evaluated in Asia, yet few Asian countries have considered including typhoid vaccines in their vaccination programs. The Diseases of the Most Impoverished ( DOMI) Program was initiated to provide evidence to decide on the introduction of typhoid vaccines in Asian countries. Methods. The centerpiece of the program is a multidisciplinary demonstration project with Vi vaccine in 5 Asian countries. The project includes epidemiologic, economic, sociobehavioral, and policy studies. Results. Policy makers want evidence on which to base their vaccine-related decisions. The DOMI Program has provided updated information on the typhoid fever burden at several Asian sites. Cost-of-illness studies found high costs to governments and individuals. Sociobehavioral studies indicated a positive attitude toward typhoid vaccines. The results of the demonstration projects indicate that mass-immunization campaigns are feasible and acceptable. Conclusions. The DOMI Program has begun to provide momentum for the evidence-based, rational introduction of typhoid vaccines into the public health programs of several Asian countries.
引用
收藏
页码:S34 / S38
页数:5
相关论文
共 28 条
[1]   PREVENTION OF TYPHOID-FEVER IN NEPAL WITH THE VI CAPSULAR POLYSACCHARIDE OF SALMONELLA-TYPHI - A PRELIMINARY-REPORT [J].
ACHARYA, IL ;
LOWE, CU ;
THAPA, R ;
GURUBACHARYA, VL ;
SHRESTHA, MB ;
CADOZ, M ;
SCHULZ, D ;
ARMAND, J ;
BRYLA, DA ;
TROLLFORS, B ;
CRAMTON, T ;
SCHNEERSON, R ;
ROBBINS, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (18) :1101-1104
[2]   A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design [J].
Acosta, CJ ;
Galindo, CM ;
Ali, M ;
Abu Elyazeed, R ;
Ochiai, RL ;
Danovaro-Holliday, MC ;
Page, AL ;
Thiem, VD ;
Jin, Y ;
Park, JK ;
Lee, H ;
Puri, MK ;
Ivanoff, B ;
Agtini, MD ;
Soeharno, R ;
Simanjuntak, CH ;
Punjabi, NH ;
Canh, DG ;
Sur, D ;
Nizami, Q ;
Manna, B ;
Dong, BQ ;
Anh, DD ;
Yang, HH ;
Bhattacharya, SK ;
Bhutta, Z ;
Trach, DD ;
Xu, ZY ;
Pang, TK ;
Donner, A ;
Clemens, JD .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2005, 10 (12) :1219-1228
[3]   Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up [J].
Acosta, CJ ;
Yang, HH ;
Wang, N ;
Gao, Q ;
Deng, Q ;
Ma, XL ;
Zhou, BD ;
Wei, L ;
Danovaro-Holliday, MC ;
Ochiai, RL ;
Wang, XY ;
Kim, DR ;
Xu, ZY ;
Dong, BQ ;
Galindo, CM ;
Clemens, JD .
VACCINE, 2005, 23 (48-49) :5618-5623
[4]  
Bahl R, 2004, J HEALTH POPUL NUTR, V22, P304
[5]  
BODHIDATTA L, 1987, REV INFECT DIS, V9, P841
[6]   Bacteremic typhoid fever in children in an urban slum, Bangladesh [J].
Brooks, WA ;
Hossain, A ;
Goswami, D ;
Sharmeen, AT ;
Nahar, K ;
Alam, K ;
Ahmed, N ;
Naheed, A ;
Nair, GB ;
Luby, S ;
Breiman, RF .
EMERGING INFECTIOUS DISEASES, 2005, 11 (02) :326-329
[7]  
Chen XG, 2006, VACCINE, V24, P561, DOI [10.1016/j.vaccine.2005.08.060, 10.1016/j.vaccine.2005.12.047]
[8]  
Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346
[9]   Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia [J].
DeRoeck, D ;
Clemens, JD ;
Nyamete, A ;
Mahoney, RT .
VACCINE, 2005, 23 (21) :2762-2774
[10]   COMPARATIVE YIELD OF SALMONELLA-TYPHI FROM BLOOD AND BONE-MARROW CULTURES IN PATIENTS WITH FEVER OF UNKNOWN ORIGIN [J].
FAROOQUI, BJ ;
KHURSHID, M ;
ASHFAQ, MK ;
KHAN, MA .
JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (03) :258-259